## **Product** Data Sheet

## PROTAC IRAK4 degrader-2

 Cat. No.:
 HY-135382

 CAS No.:
 2374122-27-5

 Molecular Formula:
  $C_{57}H_{68}FN_{11}O_8S$ 


Molecular Weight: 1086.28

Target: PROTACs; IRAK

Pathway: PROTAC; Immunology/Inflammation

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.



## **BIOLOGICAL ACTIVITY**

PROTAC IRAK4 degrader-2 (Compound 9) is a PROTAC-based IRAK4 degrader that affords potent IRAK4 degradation with a DC<sub>50</sub> in peripheral blood mononuclear cells (PBMCs) cells of 151 nM. PROTAC IRAK4 degrader-2 induce a reduction of IRAK4 protein levels with a DC<sub>50</sub> of 36 nM in PBMC cells. PROTAC IRAK4 degrader-2 also leads to the inhibition of multiple cytokines in PBMCs<sup>[1]</sup>.

IC<sub>50</sub> & Target IRAK4

In Vitro

PROTAC IRAK4 degrader-2 (compound 9) (0.01~10  $\mu$ M; 22 hours; PBMCs) mediated degradation is occurring in a proteasome dependent manner<sup>[1]</sup>.

PROTAC IRAK4 degrader-2 (compound 9) (0.01~10  $\mu$ M; 24 hours; PBMCs) induces a reduction of IRAK4 protein levels [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis<sup>[1]</sup>

Cell Line:	PBMCs
Concentration:	0.01, 0.03, 0.1, 0.3, 1, 3 and 10 μM
Incubation Time:	22 and 24 hours
Result:	Induced a reduction of IRAK4 protein levels with a $DC_{50}$ value of 36 nM and IRAK4 PROTAC-mediated degradation was occurring in a proteasome dependent manner.

## **REFERENCES**

 $[1].\ Joao\ Nunes, et\ al.\ Targeting\ IRAK4\ for\ Degradation\ with\ PROTACs.\ ACS\ Med\ Chem\ Lett.\ 2019\ Jun\ 14;10(7):1081-1085.$ 

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA